CI

At a glance

ClinicalIndex Comparison Record
Phase 2Terminated· 43 enrolled
Drug / intervention
Akt Inhibitor MK2206 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01239342
NCT01239342Phase 2Terminated
Terminated
CompareCT.gov

A Randomized Phase 2 Study of MK-2206 in Comparison With Everolimus in Refractory Renal Cell Carcinoma

National Cancer Institute (NCI)·interventional·Posted Nov 11, 2010·Updated Oct 10, 2019

In Brief

A Phase 2 clinical trial evaluating Akt Inhibitor MK2206, Everolimus, and 1 other intervention for Metastatic Kidney Carcinoma and 3 related conditions. Terminated early, enrolled 43 participants across 8 sites.

Signals

Trial was terminated early

Detailed Summary

This randomized phase II trial studies the side effects and how well Akt inhibitor MK2206 or everolimus works in treating patients with kidney cancer that does not respond to treatment. Akt inhibitor MK2206 and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Everolimus may also stop the growth of kidney cancer by blocking blood flow to the tumor. It is not yet known whether Akt inhibitor MK2206 or everolimus is more effective in treating kidney cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Kidney Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
CountriesUnited States
Collaborators--

Timeline

Phase 2TerminatedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 11, 2010
Enrollment StartJan 27, 2011
Primary CompletionSep 19, 2018
TodayJul 1, 2026
Enrollment to primary: 7.6 yearsPosted 15.6 years ago

Interventions

Akt Inhibitor MK2206drug

Given PO

Everolimusdrug

Given PO

Laboratory Biomarker Analysisother

Optional correlative studies